Transforming Oncology Drug Development

Lantern Pharma is leveraging A.I., machine learning & genomics to transform the cost, pace, and timeline of oncology drug discovery and development

See how we are doing it
01
02
03

10+ Billion Data Points and Counting

We are developing our AI platform, RADR®, to accelerate the insights needed to develop therapies in the fight against cancer

Learn more about RADR®
01
02
03

A Pioneering & World Class Team Dedicated to Creating Novel & Breakthrough Precision Oncology Therapies

Conquering cancer requires bringing unique talents & individuals together for the advancement of patient care

Meet our team
01
02
03

Transforming Oncology Drug Development

Lantern Pharma is accelerating the speed, power, precision and cost of oncology drug development.

The Golden Age of A.I.

We are an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning

Explore our purpose

Precision Oncology Medicine

Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines

Explore our mission

10+ Billion Data Points and Counting

We are doing this by developing one of the largest A.I.-powered drug development platforms designed exclusively for oncology therapeutics

Explore our technology

Developing Powerful Therapeutic Agents

Lantern Pharma’s current portfolio consists of four drug candidates and an ADC program across eight tumor targets, including two phase 2 programs.

Explore our pipeline

The Golden Age of A.I.

We are an emerging, oncology-focused, clinical stage pharma at the intersection of Artificial Intelligence, Genomics, and Machine Learning

Explore our purpose

Precision Oncology Medicine

Our mission is to deliver precision oncology therapies to the right cancer patients with significantly reduced costs and timelines

Explore our Mission

10+ Billion Data Points and Counting

We are doing this by developing one of the largest A.I.-powered drug development platforms designed exclusively for oncology therapeutics

Explore our Technology

Developing Powerful Therapeutic Agents

Lantern Pharma’s current portfolio consists of four drug candidates and an ADC program across eight tumor targets, including two phase 2 programs.

Explore our Pipeline

See what others are saying about Lantern Pharma

Oncology drug development today is a perfect problem area for Artificial Intelligence

Oncology drug development is time consuming, costly, and high risk, with rates of a successful outcome (FDA drug approval) being very low. This is a perfect problem area for Lantern Pharma’s approach to drug development involving machine learning, AI, and rapid, data-driven hypothesis testing using in vitro and in vivo models.

10%

Success rate of cancer drugs in clinical trial testing

2nd

Cancer is the second leading cause of death after heart disease

$200 Billion

Current global oncology drug market

12x

Biomarker-based trials are 12 times more likely to succeed

35,000+

Oncological clinical trials launched since 2007

X
Thank you! Here's your Whitepaper
Oops! Something went wrong while submitting the form.
Panna Sharma
PRESIDENT & CEO, LANTERN PHARMA

RADR® Platform Architecture

Lantern Pharma’s pharmaceutical biotechnology solution is through the development of a process that accurately stratifies patient populations into responders and non-responders for a wide variety of oncology therapies to de-risk clinical trials, develop companion diagnostics and increase the potential for successful FDA approval with reduced costs.

Lantern Pharma actively manages an innovative patent portfolio.

90Issued Patents and Pending Applications across
14 patent families
Search or Browse Through Lantern Pharma's Patent Portfolio

Learn how we are advancing oncology drug development

Download Our Whitepaper
"We are in a golden age of A.I. where we are able to significantly impact the speed and precision at which we develop medicines."
Top